<DOC>
	<DOCNO>NCT01279395</DOCNO>
	<brief_summary>We hypothesize administration anti-inflammatory medication celecoxib , naprosyn diclofenac cause change blood plasma white blood cell patient less able efficiently process cholesterol .</brief_summary>
	<brief_title>Anti-inflammatory Agents Cholesterol Metabolism</brief_title>
	<detailed_description>Drugs inhibit cyclooxygenase ( COX ) frequently administer relieve pain inflammation , associate cardiovascular ( CV ) toxicity elevate risk acute myocardial infarction . We demonstrate drug inhibit COX-2 isoform act interfere cellular cholesterol movement suppress expression protein facilitate efflux cholesterol well enhance expression scavenger receptor mediate cholesterol uptake . We show culture THP-1 human macrophage , COX-2 inhibition drug ( celecoxib , NS398 ) COX-2 RNA silence lead foam cell transformation , critical component atherogenesis . Thus , COX-2 inhibitor act pro-atherogenic fashion series gene name `` Cholesterol Metabolic Signature . '' Alterations signature may contribute heighten risk development atherosclerotic CV disease associate prolonged use drug class . COX enzyme activity support cholesterol homeostasis catalysis prostaglandin ( PG ) production , show vitro specific subset PGs ( PGD2 PGE2 ) sufficient maintain balance . The aim project : In observational study person pharmacologic COX-2 selective inhibition ( celecoxib ) COX-1/2 inhibition ( naproxen , diclofenac ) , document treatment effect Cholesterol Metabolic Signature isolate subject mononuclear cell na√Øve THP-1 monocytes/macrophages expose subject plasma . This allow detection variation degree pro-atherogenic response Cholesterol Metabolic Signature COX inhibition within human patient may associate high likelihood develop CV sequela . Understanding nature association COX inhibition cholesterol metabolism , extent may promote atherosclerotic CV disease , critical importance develop analgesic anti-inflammatory medication favorable risk profile . The knowledge gain may also improve clinical decision-making identify subset patient vulnerable adverse CV effect COX inhibition .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Age 4070 , osteoarthritis , male female know autoimmune inflammatory rheumatic condition , renal disease , current recent ( &gt; 1 month ) corticosteroid statin treatment , contraindication medication ( i.e . take oral anticoagulant , e.g . warfarin ) , pregnant try become pregnant breastfeeding . Participants consume medication contain aspirin NSAIDs least 2 week trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>cholesterol</keyword>
	<keyword>cyclooxygenase</keyword>
	<keyword>gene expression</keyword>
	<keyword>lipid metabolism</keyword>
</DOC>